Login

Financial Snapshot

Revenue
TTM
$788.4M
Gross Margin
TTM
12.39%
Net Income
TTM
-$103.5M
Current Assets
2025 Q4
$762.9M
Current Liabilities
2025 Q4
$368.1M
Current Ratio
2025 Q4
207.28%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
$900.2M
Book Value
2025 Q4
813.7M
Cash
2025 Q4
$418.5M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$91.80M

Stock Price

Loading...
Market Cap: $905.17 Million

About Evotec SE

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Industry: Pharmaceutical Preparations

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support